Salarius Pharmaceuticals Inc

NASDAQ:SLRX  
1.35
+0.13 (+10.66%)
Earnings Announcements

Salarius Pharmaceuticals Posts Qtrly Loss Per Common Share $0.10

Published: 03/18/2021 21:15 GMT
Salarius Pharmaceuticals Inc (SLRX) - Salarius Pharmaceuticals Reports Business Highlights With Fourth Quarter and Full-year 2020 Financial Results.
Salarius Pharmaceuticals - Qtrly Loss per Common Share $0.10.
Q4 Earnings per Share View $-0.11 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $1.37 Million
Adjusted EPS is expected to be -$0.06

Next Quarter Revenue Guidance is expected to be $1.37 Million
Next Quarter EPS Guidance is expected to be -$0.06

More details on our Analysts Page.